fenofibrate / Generic mfg. - LARVOL DELTA

FAME 1 EYE: The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. (clinicaltrials.gov) - P3 | N=450 | Active, not recruiting | Sponsor: University of Sydney | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Diabetic Nephropathy • Diabetic Retinopathy • Metabolic Disorders • Nephrology • Renal Disease • Retinal Disorders • Type 1 Diabetes Mellitus

High-throughput screening identifies paullinic acid as an antiviral agent against Bombyx mori nucleopolyhedrovirus. (PubMed, Pestic Biochem Physiol) - "Additional screening identified cyclosporin A and 1-methylinosine, and Fenofibrate as potential inhibitors. These findings validate natural products as promising sources for anti-BmNPV therapeutics and highlight lipid modulation as a novel antiviral strategy for sericulture industry."

Journal • Metabolic Disorders

Capparis spinosa Attenuates Hepatic Inflammation and Fibrosis by Suppressing Inflammatory Cytokines in a Wistar Rat Model of Nonalcoholic Steatohepatitis. (PubMed, Iran J Pharm Res) - "This research aimed to examine the impact of an aqueous extract of Capparis spinosa fruit and the lipid-lowering agent fenofibrate (FENO) on hepatic inflammation and steatosis in rats subjected to a high-fat emulsion...Our findings suggest that C. spinosa has a positive anti-inflammatory effect and may protect the liver against hepatic fibrosis, inflammation, and steatosis. These findings demonstrate the promising therapeutic potential of C. spinosa in the management of NASH."

Journal • Preclinical • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • CCL2 • IL6 • LEP • TGFB1 • TNFA

Autonomous AI Agents Discover Aging Interventions from Millions of Molecular Profiles. (PubMed, bioRxiv) - "Reanalyzing 43,602 intervention-control comparisons through multiple aging biomarkers revealed thousands of age-modifying effects missed by original investigators, including over 500 interventions that significantly reduce biological age (e.g., ouabain, KMO inhibitor, fenofibrate, and NF1 knockout)...We further experimentally validated ouabain, a top-scoring AI-identified candidate, demonstrating reduced frailty progression, decreased neuroinflammation, and improved cardiac function in aged mice. ClockBase Agent establishes a paradigm where specialized AI agents systematically reanalyze all prior research to identify age-modifying interventions autonomously, transforming how we extract biological insights from existing data to advance human healthspan and longevity."

Journal • Inflammation • NF1

Therapeutic Modulation of IL-6/STAT-3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study. (PubMed, Pharmacotherapy) - P2/3 | "Fenofibrate may represent a promising add-on therapy in patients with mild-to-moderate UC by modulating inflammation and improving QoL."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CRP • IL6 • PPARA • STAT3 • TCF3

Continuous-Flow Electrochemical Oxidation of Alkylarenes and Diarylmethanes to Aromatic Ketones Using Water under Catalyst-, Mediator-, and Additive-Free Conditions. (PubMed, J Org Chem) - "No additional electrocatalysts, redox mediators, additives, or chemical oxidants were required, highlighting the environmental friendliness and sustainability of this continuous-flow electrochemical protocol. Furthermore, the synthetic utility of this approach has been demonstrated by the gram-scale syntheses of a Celestolide derivative, a Fenofibrate derivative, and an anthraquinone."

Journal

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Han Ying | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Aug 2025 | Trial primary completion date: Dec 2026 ➔ Aug 2025

Trial completion • Trial completion date • Trial primary completion date • Hepatology • Immunology • Primary Biliary Cholangitis

COMPARATIVE ASSESSMENT OF THE EFFECT OF SILYMARIN, FENOFIBRATE, BETAINE AND ADEMETIONINE ON THE DEVELOPMENT OF STEATOHEPATITIS IN WISTAR RATS. (PubMed, Georgian Med News) - "Fenofibrate was the most effective agent in preventing fructose-induced hepatic steatosis and transaminase elevation, in line with activation of PPAR-α-dependent β-oxidation and inhibition of lipogenesis."

Clinical • Journal • Preclinical • Hepatology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Formulation of α-Linolenic Acid-Based Microemulsions for Age-Related Macular Degeneration: Physicochemical Tests and HET-CAM Assays for Anti-Angiogenic Activities. (PubMed, Medicina (Kaunas)) - " ME3, with an average particle size of 38.59 nm, was selected as the optimized formulation for developing drug-loaded ME containing Fenofibrate, Axitinib, and Sirolimus. Treatment with the optimized blank ME and Sirolimus ME significantly (p < 0.05) reduced COX-2 protein expression in LPS-stimulated RAW 264.7 cells, suggesting their potential anti-inflammatory effects. Overall, we suggest that the α-linolenic acid-based Sirolimus microemulsion may serve as a promising topical therapeutic approach for managing AMD and offering a potential alternative to invasive intravitreal injections."

Journal • Age-related Macular Degeneration • Cataract • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • PTGS2

Unraveling the Function of PPARα in Neurodegenerative Disorders: A Potential Pathway to Novel Therapies. (PubMed, Biomedicines) - "Indicatively, gemfibrozil (PPARα agonist) markedly reduced the beta-amyloid burden, microgliosis, and astrogliosis in the hippocampus of 5xFAD mice and ameliorated their spatial learning and memory. Fenofibrate (PPARα agonist) reduced the depressive-like behavior and memory deficits in rotenone-lesioned rats developing Parkinsonism...Although current findings are promising, they underscore the necessity of further rigorous clinical validation of the efficacy of various PPARα agonists in the retardation or even prevention of AD and PD symptomatology in both genders and the development of reliable biomarkers for the early assessment of the impact of PPARα agonists on NDs. The safety of these drugs in the elderly and their longitudinal effectiveness should also be evaluated."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • PPARA

Aberrant lipid metabolism renders an aggressive behavior of T-lymphoblastic lymphoma in a MASH model. (PubMed, Oncogene) - "Wnt/β-catenin signaling could be a potential lymphomagenetic mechanism for extranodal infiltration of T-lymphoblastic lymphoma. Fenofibrate has the potential to be an effective therapeutic strategy against liver infiltration of T-lymphoblastic lymphoma in MASH liver."

Journal • Hematological Malignancies • Hepatology • Liver Cancer • Lymphoma • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • FGF21 • PPARA

Peroxisome proliferator-activated receptors as novel targets of small cell lung cancer circulating tumor cells. (PubMed, Neoplasma) - "Cytotoxicity varied by compound, while the PPARγ agonist pioglitazone and the PPARα agonist fenofibrate were preferentially active in CTC lines, DG172 hydrochloride was selective for pleural effusion-derived lines, while rosiglitazone maleate, cloxiquine, and agrimol B showed no selectivity. These findings support PPARs as clinically relevant targets in SCLC, with PPAR-directed agents showing cytotoxic effects comparable to those reported in other malignancies. Such agents may aid SCLC treatment and help delineate biological differences between CTCs and resident tumor cells."

Circulating tumor cells • Journal • Lung Cancer • Oncology • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • BCL2 • BCL2L1 • CASP3 • CASP9 • CFLAR • CTCs • CXCR4 • ICAM1 • PPARA

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Differential Pre- and Post-Treatment Effects of Low-Dose Antidyslipidemic Drugs on Gentamicin-Induced Acute Nephrotoxicity in the Rat: A Histopathological and Biochemical Study. (PubMed, J Appl Toxicol) - "In conclusion, low-dose fenofibrate pre-treatment but not post-treatment considerably prevented gentamicin-induced acute tubular necrosis and renal functional abnormalities. Despite effective prevention of gentamicin-induced acute tubular necrosis, pre-treatment with low-dose rosuvastatin provided partial protection against renal functional abnormalities, while its post-treatment was markedly ineffective."

Journal • Preclinical • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • TNFA

Albuminuria Drives Type 2 Diabetes-Related Atrial Fibrillation: an ACCORD substudy (AHA 2025) - "Albuminuria independently associates with incident AF in high-risk T2D patients. Whether modifying albuminuria alters AF risk is worthy of further exploration."

Atrial Fibrillation • Cardiovascular • Diabetes • Hypertension • Inflammation • Metabolic Disorders • Renal Disease • Type 2 Diabetes Mellitus

A QSPR study of coronary artery disease drugs using eccentricity-based indices. (PubMed, Sci Rep) - "This study advances QSPR modeling by using eccentricity-based graphical invariants, specifically designed to enhance the predictive accuracy for physicochemical properties of drugs used to treat coronary artery disease, including atorvastatin, simvastatin, rosuvastatin, aspirin, clopidogrel, metoprolol, atenolol, enalapril, lisinopril, amlodipine, diltiazem, nitroglycerin, isosorbide dinitrate, ranolazine, gemfibrozil, and fenofibrate. The experimental values were compared with forecasted data, revealing a strong correlation between them. This demonstrates the reliability of our regression models in assessing these vital physicochemical parameters."

Journal • Cardiovascular • Coronary Artery Disease

Lipidomics and single-cell transcriptomics uncover aberrant lipid metabolism in metaplasia lesions during gastric carcinogenesis. (PubMed, J Gastroenterol) - "Our study reveals a distinct lipid signature in gastric metaplasia characterized by TG and LD accumulation, providing novel therapeutic insights into targeting lipid metabolism to prevent GIM malignant transformation and reduce cancer risk."

Journal • Gastric Cancer • Gastrointestinal Disorder • Infectious Disease • Metabolic Disorders • Oncology • Solid Tumor • DDIT4 • FABP1

Fenofibrate as a Modulator of the Renin-Angiotensin System in Su/Hx-Induced Pulmonary Arterial Hypertension. (PubMed, Int J Mol Sci) - "We evaluated the effects of fenofibrate (FF) in a SU5416/hypoxia model of pulmonary arterial hypertension (PAH) with a specific focus on its influence on the renin-angiotensin system (RAS). In the RV, Ang-(1-7) increased, ACE2 was preserved, and NO2- and NO3 levels were maintained. FF exerts protective effects in Su/Hx-induced PAH."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • RAS

Selective Peroxisome Proliferator-Activated Receptor-α (PPARα) Modulator Inhibits Cyst Enlargement in PKD (KIDNEY WEEK 2025) - "Although fenofibrate, a PPARα modulator, has been reported to suppress renal cyst enlargement, it has not yet been applied clinically due to concerns about renal metabolism and nephrotoxicity. Conclusion The favorable effects of pemafibrate in animal models of cystic kidney disease and cellular experiments demonstrated its potential as a clinical treatment for ADPKD. We will evaluate the optimal dosage and toxicity of pemafibrate treatment."

Autosomal Dominant Polycystic Kidney Disease • Fibrosis • Genetic Disorders • Immunology • Nephrology • Polycystic Kidney Disease • Renal Disease • PPARA

Fenofibrate Attenuates Kidney Injury by Enhancing Use of Fatty Acids from Lipid Droplets in Proximal Tubules (KIDNEY WEEK 2025) - "SnRNA-seq also showed a reduction in transcripts involved in utilization of lipid droplets ( Lpin2, Gpat4, Gpam, and Dgat1 ) in PT cells in Klf15 PTKO as compared to Klf15 fl/fl mice post-AAI. Conclusion PPARα-KLF15 agonism attenuates AKI to CKD transition by enhancing fatty acid oxidation metabolism through increased utilization of lipid droplets in PT cells post-AAI treatment."

Chronic Kidney Disease • Fibrosis • Immunology • Renal Disease • ACOX1 • COL1A1 • CPT1A • KLF5 • PLIN2 • PPARA • PPARGC1A • VIM

Nationwide Analysis of Progressive Kidney Function Decline and Diabetic Macular Edema in Type 2 Diabetes. (PubMed, Ophthalmol Sci) - "Propensity score matching balanced covariates including age, sex, race/ethnicity, hemoglobin A1c, hypertension, hyperlipidemia, insulin and oral hypoglycemic agent use, fenofibrate use, prostaglandin analog use, and Diabetes Complications Severity Index components...These results underscore the need for proactive ophthalmic screening in diabetic patients with impaired renal function and suggest renal improvement may mitigate DME risk. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Macular Edema • Diabetic Nephropathy • Diabetic Retinopathy • Dyslipidemia • Hypertension • Metabolic Disorders • Nephrology • Ophthalmology • Renal Disease • Retinal Disorders • Transplantation • Type 2 Diabetes Mellitus

Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR γ activity. (PubMed, Int Immunopharmacol) - "Initially, molecular docking was performed using a panel of fibrate-class compounds (including pemafibrate, bezafibrate, fenofibrate, gemfibrozil, and clofibrate) against the ligand-binding domain of PPAR-γ (PDB ID: 7WGO). These findings suggest that bezafibrate, selected through integrative computational and pharmacological screening, effectively ameliorates experimental autoimmune arthritis via PPAR-γ activation. This highlights its promise as a repurposed therapeutic candidate and warrants further investigation."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL1B • IL6 • TNFA

Beyond Weight Clinical Biochemical Evolution in a Patient With Obesity Treated Comprehensively at a Mexican Clinic (OBESITY WEEK 2025) - "Her pharmacological treatment focused on discontinuing insulin and gradually increasing the use of semaglutide, starting at 0.25 mg and increasing to 0.50 mg, and fenofibrate/simvastatin (145/40 mg); supplementation with omega-3 fatty acids (DHA and EPA) and probiotics ( Bifidobacterium lactis BPL1®); the results are shown below. The results obtained in this clinical case suggest that lifestyle modification, a healthy diet, drug treatment, and supplementation have a positive impact on BMI (kg/m2 ) , body composition, and biochemical values in patients living with obesity. Specialized obesity management clinics that integrate all of these factors into their treatment are essential."

Clinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Targeting metabolic dysfunction-associated steatotic liver disease with phytosomal silymarin and piperine: A natural alternative to fenofibrate in a rat model. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This study evaluated a novel phytosomal silymarin formulation co-administered with piperine and lecithin, compared to fenofibrate, in an oxytetracycline-induced MASLD rat model. This study demonstrates the potential of a phytosomal silymarin-piperine-lecithin complex as a natural therapeutic avenue for MASLD, outperforming a conventional lipid-lowering agent in this animal model. Future clinical and pharmacokinetic studies are warranted."

Journal • Preclinical • Hepatology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • PPARA

Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) (clinicaltrials.gov) - P4 | N=44 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology • Pain